TRANSTHERA-B (02617.HK): H Share Full Circulation Completed
NewTimeSpace News: On 19 November 2026, TransThera Sciences (Nanjing), Inc. (stock code: 02617.HK) said the conversion of 44,971,128 unlisted shares held by 10 participating shareholders into H shares was completed on the same day, with the converted H shares to begin trading on the Exchange at 9:00 a.m. on 20 November 2026.
Upon completion, H shares increased from 313,347,673 to 358,318,801, raising their proportion from 76.69% to 87.70%, while unlisted shares fell from 95,230,960 to 50,259,832, or from 23.31% to 12.30%. Total issued shares remain unchanged at 408,578,633.
The company had published announcements on 20 October 2025, 26 October 2026 and 1 November 2026 regarding the proposed implementation of H share full circulation, the CSRC filing notice and the Stock Exchange's listing approval.
- TRANSTHERA-B (02617.HK) HKEX approves H-share full circulation of 44.97m shares
- TransThera-B (02617.HK): Yochanra® begins nationwide sales
- TRANSTHERA-B (02617.HK): Tinengotinib Included in CSCO Guidelines for Biliary Tract Malignancies (2026)
- TRANSTHERA-B(02617.HK): 2026 Interim Report - Profit Attributable to Shareholders stood at loss of CNY 95.47 million, loss narrowed by 22.3% YoY
- TRANSTHERA-B (02617.HK): Class 1 New Drug Jientai (Tiengotinib Tablets) Receives Conditional NMPA Approval for FGFR2 Fusion Advanced Cholangiocarcinoma